<DOC>
	<DOCNO>NCT00034710</DOCNO>
	<brief_summary>The purpose study gain initial information tolerability high-dose capsaicin patch patient Painful Postherpetic Neuralgia . The study also collect preliminary information safety efficacy .</brief_summary>
	<brief_title>Pilot Study High-Dose Capsaicin Patches Treat Postherpetic Neuralgia Pain</brief_title>
	<detailed_description />
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Eligibility Criteria Patients may eligible study : Have diagnosis Painful Postherpetic Neuralgia least 6 month post vesicle crusting . Are good health . Have adequate pain score screening period . Have painful area ( maximum two site ) neck . If female , nonchildbearing ability define absence menses minimum 3 month surgically sterile . If male , willing agree take adequate birth control precaution partner 60 day follow experimental drug exposure . Have unbroken skin good perfusion painful area ( ) . Have ability feel capsaicinmediated sensation , evidence ability feel topically apply OTC capsaicin cream . Are stable continuous medication regimen , change dosage 21 day prior study start , willing maintain concomitant medication current dos throughout study . Are willing able use oral opioidbased analgesic agent relief , case need relieve acute pain associate application capsaicin patch . Are 18 year age old . Are willing able comply protocol Patients eligible study : Have diffusely distribute neuropathic pain ( i.e. , pain evident 2 different site ) . Subjects must significant pain outside area treat . Have implant medical device ( spinal cord stimulator , intrathecal pump peripheral nerve stimulator ) treatment neuropathic pain . Currently ( within past 21 day ) use topically apply nonsteroidal antiinflammatory drug , local anesthetic , steroid capsaicin product painful area . Currently ( within past 21 day ) use topical agent lidoderm patch 5 % , topical steroid aspirin . Have history current problem prescription drug illicit substance abuse ( self report judge investigator ) . Currently abuse problem alcohol ( selfreport judge investigator ) . Are suspected psychosocial gain/benefit continue pain judge investigator primary treat physician . Plan travel 100 mile home study engage unusual activity might exacerbate pain . Have poor cardiac , renal , hepatic , pulmonary function judge investigator primary treat physician . Have laboratory value screen outside normal range , unless judge investigator clinically significant appropriate evaluation . Have hypersensitivity capsaicin ( i.e. , chili pepper OTC capsaicin product ) , local anesthetic , oral opioidbased analgesic agent , adhesive . Have high tolerance opioids . Currently use Class 1 antiarrhythmic drug ( tocainide mexiletine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Analgesics/*therapeutic use</keyword>
	<keyword>Capsaicin/*administration &amp; dosage/adverse effect</keyword>
	<keyword>Herpes Zoster/*complications/drug therapy</keyword>
	<keyword>Neuralgia/*drug therapy/etiology</keyword>
	<keyword>Pain</keyword>
	<keyword>Capsicum</keyword>
	<keyword>Pepper</keyword>
	<keyword>Dermal assessment</keyword>
	<keyword>Pain measurement</keyword>
	<keyword>Diary</keyword>
	<keyword>PHN</keyword>
	<keyword>Postherpetic Neuralgia</keyword>
	<keyword>allodynia</keyword>
	<keyword>hyperalgesia</keyword>
	<keyword>shingle</keyword>
	<keyword>varicella</keyword>
</DOC>